These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 24337604)

  • 21. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction of
    Guo X; Zhou N; Chen Z; Liu T; Xu X; Lei X; Shen L; Gao J; Yang Z; Zhu H
    Gastric Cancer; 2020 Jul; 23(4):614-626. PubMed ID: 31919745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive Detection of HER2 Expression in Gastric Cancer by
    Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
    Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
    Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
    J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
    Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
    J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Bensch F; Brouwers AH; Lub-de Hooge MN; de Jong JR; van der Vegt B; Sleijfer S; de Vries EGE; Schröder CP
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2300-2306. PubMed ID: 30058029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary clinical trial to evaluate
    Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Kim KI; Lee KC; Kang JH; Seong MK; Kim HA; Noh WC; Lim SM
    EJNMMI Res; 2021 Jan; 11(1):8. PubMed ID: 33475899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
    Eisses B; van Geel JJL; Brouwers AH; Bensch F; Elias SG; Kuip EJM; Jager A; van der Vegt B; Lub-de Hooge MN; Emmering J; Arens AIJ; Zwezerijnen GJC; Vugts DJ; Menke-van der Houven van Oordt CW; de Vries EGE; Schröder CP
    J Nucl Med; 2024 Oct; 65(10):1540-1547. PubMed ID: 39237347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
    Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
    Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
    Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
    Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
    Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
    Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.